[1] Keyvani V, Kheradmand N, Navaei ZN, et al. Epidemiological trends and risk factors of gynecological cancers: an update. Med Oncol, 2023; 40, 93. doi:  10.1007/s12032-023-01957-3
[2] Bray F, Laversanne M, Sung H, et al. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin, 2024; 74, 229−63. doi:  10.3322/caac.21834
[3] Ino K. Indoleamine 2, 3-dioxygenase and immune tolerance in ovarian cancer. Curr Opin Obstet Gynecol, 2011; 23, 13−8. doi:  10.1097/GCO.0b013e3283409c79
[4] Yoshida Y, Schmaltz CL, Jackson-Thompson J, et al. Ovarian cancer survival in Missouri, 1996-2014. Mo Med, 2018; 115, 542−7.
[5] Baldwin LA, Huang B, Miller RW, et al. Ten-year relative survival for epithelial ovarian cancer. Obstet Gynecol, 2012; 120, 612−8. doi:  10.1097/AOG.0b013e318264f794
[6] Wang Y, Wang J, Xu YY, et al. Survival trend of cervical cancer in Qidong city of Jiangsu province from 1977 to 2016. China Cancer, 2022; 31, 782−6. (In Chinese
[7] Deng SM, Li N, Liang Y, et al. Analysis of survival in major malignances during 2008-2013 in Jiulongpo avea of Chongqing. Chin J Cancer Prev Treat, 2014; 21, 1223−6. (In Chinese
[8] Gong WW, Luo SL, Hu RY, et al. Analysis of survival rate of breast, cervical, and ovarian cancer patients during 2005-2010 in Zhejiang province, China. Chin J Prev Med, 2014; 48, 366−9. (In Chinese
[9] Li YH, Lu YQ, Ling W, et al. Survival analysis of patients with malignant tumors in Sihui city between 1987 and 2009. China Cancer, 2017; 26, 596−600. (In Chinese
[10] Zhou J, Su X, Li L, et al. Survival rate among the main cancer patients in three countys of GuiZhou province, 2013~2015. Studies Trace Elem Health, 2020; 37, 54−6. (In Chinese
[11] Zhang WW, Wang LJ. Analysis of cancer incidence and survival in Anshan City from 2008 to 2017. J Community Med, 2021; 19, 530−5. (In Chinese
[12] Han X, Huang CX, Zhao J, et al. Incidence and survival analysis of cervical cancer patients among permanent residents in Yangpu district of Shanghai during 2002-2012. Acad J Second Military Med Univ, 2014; 35, 26−9. (In Chinese doi:  10.3724/SP.J.1008.2014.00026
[13] Xiang YB, Jin F, Chen HQ, et al. An analysis of survival rate of patients with malignancy in urban district of Shanghai from 1988 to 1991. China Cancer, 1996; 5, 6-8. (In Chinese
[14] Wang QS, Lin XP, Li RT, et al. An analysis of relative survival rate in patients with malignancy in Tianjin. China Cancer, 2001; 10, 276−7. (In Chinese
[15] Kim IS, Suh I, Oh HC, et al. Incidence and survival of cancer in Kangwha County (1983-1987). Yonsei Med J, 1989; 30, 256−68. doi:  10.3349/ymj.1989.30.3.256
[16] Muhamad NA, Kamaluddin MA, Adon MY, et al. cia. Asian Pac J Cancer Prev, 2015; 16, 3067−72. doi:  10.7314/APJCP.2015.16.7.3067
[17] Sriamporn S, Swaminathan R, Parkin DM, et al. Loss-adjusted survival of cervix cancer in Khon Kaen, Northeast Thailand. Br J Cancer, 2004; 91, 106−10. doi:  10.1038/sj.bjc.6601959
[18] Chia KS, Du WB, Sankaranarayanan R, et al. Population-based cancer survival in Singapore, 1968 to 1992: an overview. Int J Cancer, 2001; 93, 142−7. doi:  10.1002/ijc.1293
[19] Nandakumar A, Anantha N, Venugopal TC. Incidence, mortality and survival in cancer of the cervix in Bangalore, India. Br J Cancer, 1995; 71, 1348−52. doi:  10.1038/bjc.1995.262
[20] Yeole BB, Kumar AVR, Kurkure A, et al. Population-based survival from cancers of breast, cervix and ovary in women in Mumbai, India. Asian Pac J Cancer Prev, 2004; 5, 308−15.
[21] Swaminathan R, Selvakumaran R, Esmy PO, et al. Cancer pattern and survival in a rural district in South India. Cancer Epidemiol, 2009; 33, 325−31. doi:  10.1016/j.canep.2009.09.008
[22] Fantin R, Santamaría-Ulloa C, Barboza-Solís C. Social inequalities in cancer survival: A population-based study using the Costa Rican Cancer Registry. Cancer Epidemiol, 2020; 65, 101695. doi:  10.1016/j.canep.2020.101695
[23] Arias-Ortiz NE, de Vries E. Health inequities and cancer survival in Manizales, Colombia: a population-based study. Colomb Med (Cali), 2018; 49, 63−72. doi:  10.25100/cm.v49i1.3629
[24] Booth CM, Li G, Zhang-Salomons J, et al. The impact of socioeconomic status on stage of cancer at diagnosis and survival: a population-based study in Ontario, Canada. Cancer, 2010; 116, 4160−7. doi:  10.1002/cncr.25427
[25] Pearcey R, Miao Q, Kong WD, et al. Impact of adoption of chemoradiotherapy on the outcome of cervical cancer in Ontario: results of a population-based cohort study. J Clin Oncol, 2007; 25, 2383−8. doi:  10.1200/JCO.2006.09.1926
[26] Hislop GT, Bajdik CD, Regier MD, et al. Ethnic differences in survival for female cancers of the breast, cervix and colorectum in British Columbia, Canada. Asian Pac J Cancer Prev, 2007; 8, 209−14.
[27] Boschmonar MCG, Chaviano PJJ, García AAM, et al. Trends in survival rates of cancer in Cuba. Eur J Epidemiol, 1999; 15, 521−8. doi:  10.1023/A:1007587507460
[28] Sant M, Allemani C, Santaquilani M, et al. EUROCARE-4. Survival of cancer patients diagnosed in 1995-1999. Results and commentary. Eur J Cancer, 2009; 45, 931−91. doi:  10.1016/j.ejca.2008.11.018
[29] Melan K, Janky E, Macni J, et al. Epidemiology and survival of cervical cancer in the French West-Indies: data from the Martinique Cancer Registry (2002-2011). Glob Health Action, 2017; 10, 1337341. doi:  10.1080/16549716.2017.1337341
[30] Levi F, Randimbison L, Te VC, et al. Trends in survival for patients diagnosed with cancer in Vaud, Switzerland, between 1974 and 1993. Ann Oncol, 2000; 11, 957−63. doi:  10.1023/A:1008339623847
[31] Gafà L, Amendola P, Dardanoni G, et al. Cancers of the female genital tract in Ragusa, Sicily. Eur J Epidemiol, 1995; 11, 443−6. doi:  10.1007/BF01721230
[32] Vincerževskienė I, Jasilionis D, Austys D, et al. Education predicts cervical cancer survival: a Lithuanian cohort study. Eur J Public Health, 2017; 27, 421−4.
[33] Bjurberg M, Holmberg E, Borgfeldt C, et al. Primary treatment patterns and survival of cervical cancer in Sweden: A population-based Swedish Gynecologic Cancer Group Study. Gynecol Oncol, 2019; 155, 229−36. doi:  10.1016/j.ygyno.2019.08.022
[34] Brenner H, Hakulinen T. Period versus cohort modeling of up-to-date cancer survival. Int J Cancer, 2008; 122, 898−904. doi:  10.1002/ijc.23087
[35] Chakalova G, Dimitrova N, Gavrilov I, et al. Cancer burden of breast and gynecological cancers in Bulgaria: epidemiology and clinical aspects. J BUON, 2013; 18, 1038−44.
[36] Waldmann A, Eisemann N, Katalinic A. Epidemiology of malignant cervical, corpus uteri and ovarian tumours - current data and epidemiological trends. Geburtshilfe Frauenheilkd, 2013; 73, 123−9. doi:  10.1055/s-0032-1328266
[37] Diaz A, Baade PD, Valery PC, et al. Comorbidity and cervical cancer survival of Indigenous and non-Indigenous Australian women: A semi-national registry-based cohort study (2003-2012). PLoS One, 2018; 13, e0196764. doi:  10.1371/journal.pone.0196764
[38] Gondos A, Brenner H, Wabinga H, et al. Cancer survival in Kampala, Uganda. Br J Cancer, 2005; 92, 1808−12. doi:  10.1038/sj.bjc.6602540
[39] Wabinga H, Ramanakumar AV, Banura C, et al. Survival of cervix cancer patients in Kampala, Uganda: 1995-1997. Br J Cancer, 2003; 89, 65−9. doi:  10.1038/sj.bjc.6601034
[40] Gultekin M, Dundar S, Kucukyildiz I. Survival of gynecological cancers in Turkey: where are we at? J Gynecol Oncol. 2017; 28:e85.
[41] Berrino F, De Angelis R, Sant M. Survival for eight major cancers and all cancers combined for European adults diagnosed in 1995-99: results of the EUROCARE-4 study. Lancet Oncol. 2007; 8:773-83 .
[42] Chen JG, Zhu J, Zhang YH. An analysis of survival in major malignancies during 1972-2000 in Qidong, China. China Cancer, 2006; 15, 575−8. (In Chinese
[43] Li YH, Huang QH, Lin X, et al. Survival rates of malignancies and nasopharyngeal carcinoma during 2003-2005 in Sihui city. Chin J Cancer Prev Treat, 2013; 20, 734−6. (In Chinese
[44] Arab M, Khayamzadeh M, Mohit M, et al. Survival of ovarian cancer in Iran: 2000-2004. Asian Pac J Cancer Prev, 2009; 10, 555−8.
[45] Brenner H, Stegmaier C, Ziegler H. Trends in survival of patients with ovarian cancer in Saarland, Germany, 1976-1995. J Cancer Res Clin Oncol, 1999; 125, 109−13. doi:  10.1007/s004320050250
[46] Dahm-Kähler P, Borgfeldt C, Holmberg E, et al. Population-based study of survival for women with serous cancer of the ovary, fallopian tube, peritoneum or undesignated origin - on behalf of the Swedish Gynecological Cancer Group (SweGCG). Gynecol Oncol, 2017; 144, 167−73. doi:  10.1016/j.ygyno.2016.10.039
[47] De Angelis R, Sant M, Coleman MP, et al. Cancer survival in Europe 1999-2007 by country and age: results of EUROCARE-5-a population-based study. Lancet Oncol, 2014; 15, 23−34. doi:  10.1016/S1470-2045(13)70546-1
[48] Grann AF, Thomsen RW, Jacobsen JB, et al. Comorbidity and survival of Danish ovarian cancer patients from 2000-2011: a population-based cohort study. Clin Epidemiol, 2013; 5, 57−63.
[49] Mahdy NH, Abdel-Fattah M, Ghanem H. Ovarian cancer in Alexandria from 1988 to 1997: trends and survival. East Mediterr Health J, 1999; 5, 727−39. doi:  10.26719/1999.5.4.727
[50] Nilsson B, Gustavson-Kadaka E, Hakulinen T, et al. Cancer survival in Estonian migrants to Sweden. J Epidemiol Community Health, 1997; 51, 418−23. doi:  10.1136/jech.51.4.418
[51] Okongo F, Ogwang DM, Liu BY, et al. Cancer incidence in Northern Uganda (2013–2016). Int J Cancer, 2019; 144, 2985−91. doi:  10.1002/ijc.32053
[52] Trétarre B, Molinié F, Woronoff AS, et al. Ovarian cancer in France: trends in incidence, mortality and survival, 1980-2012. Gynecol Oncol, 2015; 139, 324−9. doi:  10.1016/j.ygyno.2015.09.013
[53] Zhou Y, Xiang ZS, Ma JY, et al. Survival of cancer patients in Fujian, Southeast China: a population-based cancer registry study. Neoplasma, 2021; 68, 892−8. doi:  10.4149/neo_2021_210203N168
[54] Li HZ, Du LB, Li QL, et al. Cancer survival in Haining and Jiashan cancer registry areas of Zhejiang province. China Cancer, 2020; 29, 14−21. (In Chinese
[55] Cheung FY, Mang OWK, Law SCK. A population-based analysis of incidence, mortality, and stage-specific survival of cervical cancer patients in Hong Kong: 1997-2006. Hong Kong Med J, 2011; 17, 89−95.
[56] Chiang CJ, Lo WC, Yang YW, et al. Incidence and survival of adult cancer patients in Taiwan, 2002-2012. J Formos Med Assoc, 2016; 115, 1076−88. doi:  10.1016/j.jfma.2015.10.011
[57] Matsuda T, Ajiki W, Marugame T, et al. Population-based survival of cancer patients diagnosed between 1993 and 1999 in Japan: a chronological and international comparative study. Jpn J Clin Oncol, 2011; 41, 40−51. doi:  10.1093/jjco/hyq167
[58] Yagi A, Ueda Y, Kakuda M, et al. Epidemiologic and clinical analysis of cervical cancer using data from the population-based Osaka Cancer Registry. Cancer Res, 2019; 79, 1252−9.
[59] Kang MJ, Won YJ, Lee JJ, et al. Cancer statistics in Korea: incidence, mortality, survival, and prevalence in 2019. Cancer Res Treat, 2022; 54, 330−44. doi:  10.4143/crt.2022.128
[60] Shin DW, Bae J, Ha J, et al. Conditional relative survival of cervical cancer: a Korean National Cancer Registry Study. J Gynecol Oncol, 2021; 32, e5. doi:  10.3802/jgo.2021.32.e5
[61] Maláková K, Cabasag CJ, Bardot A, et al. Cancer survival in Thailand from 1997 to 2012: assessing the impact of universal health coverage. J Cancer Policy, 2022; 34, 100353. doi:  10.1016/j.jcpo.2022.100353
[62] Laudico AV, Mirasol-Lumague MR, Mapua CA, et al. Cancer incidence and survival in Metro Manila and Rizal province, Philippines. Jpn J Clin Oncol, 2010; 40, 603−12. doi:  10.1093/jjco/hyq034
[63] Alawadhi E, Al-Awadi A, Elbasmi A, et al. Cancer survival by stage at diagnosis in Kuwait: a population-based study. J Oncol, 2019; 2019, 8463195.
[64] Gultekin M, Dundar S, Kucukyildiz I, et al. Survival of gynecological cancers in Turkey: where are we at?. J Gynecol Oncol, 2017; 28, e85. doi:  10.3802/jgo.2017.28.e85
[65] Gatta G, Lasota MB, Verdecchia A. Survival of European women with gynaecological tumours, during the period 1978-1989. Eur J Cancer, 1998; 34, 2218−25. doi:  10.1016/S0959-8049(98)00326-8
[66] Bielska-Lasota M, Inghelmann R, van de Poll-Franse L, et al. Trends in cervical cancer survival in Europe, 1983-1994: a population-based study. Gynecol Oncol, 2007; 105, 609−19. doi:  10.1016/j.ygyno.2007.01.048
[67] Jensen KE, Hannibal CG, Nielsen A, et al. Social inequality and incidence of and survival from cancer of the female genital organs in a population-based study in Denmark, 1994-2003. Eur J Cancer, 2008; 44, 2003−17. doi:  10.1016/j.ejca.2008.06.014
[68] Brenner H, Hakulinen T. Long-term cancer patient survival achieved by the end of the 20th century: most up-to-date estimates from the nationwide Finnish cancer registry. Br J Cancer, 2001; 85, 367−71. doi:  10.1054/bjoc.2001.1905
[69] Talbäck M, Dickman PW. Predicting the survival of cancer patients recently diagnosed in Sweden and an evaluation of predictions published in 2004. Acta Oncol, 2012; 51, 17−27. doi:  10.3109/0284186X.2011.626444
[70] Emmett M, Gildea C, Nordin A, et al. Cervical cancer - does the morphological subtype affect survival rates?. J Obstet Gynaecol, 2018; 38, 548−55. doi:  10.1080/01443615.2017.1379062
[71] Grundmann N, Meisinger C, Trepel M, et al. Trends in cancer incidence and survival in the Augsburg study region: results from the Augsburg cancer registry. BMJ Open, 2020; 10, e036176. doi:  10.1136/bmjopen-2019-036176
[72] Brenner H, Stegmaier C, Ziegler H. Long-term survival of cancer patients in Germany achieved by the beginning of the third millenium. Ann Oncol, 2005; 16, 981−6. doi:  10.1093/annonc/mdi186
[73] Levi F, La Vecchia C, Randimbison L, et al. Incidence, mortality and survival from invasive cervical cancer in Vaud, Switzerland, 1974-1991. Ann Oncol, 1994; 5, 747−52. doi:  10.1093/oxfordjournals.annonc.a058980
[74] Wenzel HHB, Bekkers RLM, Lemmens VEPP, et al. No improvement in survival of older women with cervical cancer—a nationwide study. Eur J Cancer, 2021; 151, 159−67. doi:  10.1016/j.ejca.2021.04.014
[75] Houterman S, Janssen-Heijnen MLG, van de Poll-Franse LV, et al. Higher long-term cancer survival rates in southeastern Netherlands using up-to-date period analysis. Ann Oncol, 2006; 17, 709−12. doi:  10.1093/annonc/mdj139
[76] Minelli L, Stracci F, Prandini S, et al. Gynaecological cancers in Umbria (Italy): trends of incidence, mortality and survival, 1978-1998. Eur J Obstet Gynecol Reprod Biol, 2004; 115, 59−65. doi:  10.1016/j.ejogrb.2003.11.026
[77] Pavlík T, Májek O, Büchler T, et al. Trends in stage-specific population-based survival of cancer patients in the Czech Republic in the period 2000-2008. Cancer Epidemiol, 2014; 38, 28−34. doi:  10.1016/j.canep.2013.11.002
[78] Ojamaa K, Innos K, Baburin A, et al. Trends in cervical cancer incidence and survival in Estonia from 1995 to 2014. BMC Cancer, 2018; 18, 1075. doi:  10.1186/s12885-018-5006-1
[79] Ulinskas K, Aleknaviciene B, Smailyte G. Demographic differences in cervical cancer survival in Lithuania. Open Med, 2013; 8, 16−21. doi:  10.2478/s11536-012-0051-7
[80] Bravo LE, García LS, Collazos PA. Cancer survival in Cali, Colombia: a population-based study, 1995-2004. Colomb Med (Cali), 2014; 45, 110−6. doi:  10.25100/cm.v45i3.1525
[81] Gari A, Lotocki R, Krepart G, et al. Cervical cancer in the province of Manitoba: a 30-year experience. J Obstet Gynaecol Can, 2008; 30, 788−95. doi:  10.1016/S1701-2163(16)32943-7
[82] Jemal A, Ward EM, Johnson CJ, et al. Annual report to the nation on the status of cancer, 1975-2014, featuring survival. J Natl Cancer Inst, 2017; 109, djx030.
[83] Gatta G, Capocaccia R, Coleman MP, et al. Toward a comparison of survival in American and European cancer patients. Cancer, 2000; 89, 893−900. doi:  10.1002/1097-0142(20000815)89:4<893::AID-CNCR24>3.0.CO;2-9
[84] Surveillance Research Program NCI. SEER*Explorer: An interactive website for SEER cancer statistics. https://seer.cancer.gov/statistics-network/explorer/application.html?site=1&data_type=1&graph_type=2&compareBy=sex&chk_sex_3=3&chk_sex_2=2&rate_type=2&race=1&age_range=1&hdn_stage=101&advopt_precision=1&advopt_show_ci=on&hdn_view=0&advopt_show_apc=on&advopt_display=2#resultsRegion0. [2023-06-07].
[85] Taylor R, Bell J, Coates M, et al. Cervical cancer in New South Wales women: five-year survival, 1972 to 1991. Aust N Z J Public Health, 1996; 20, 413−20. doi:  10.1111/j.1467-842X.1996.tb01055.x
[86] Yu XQ, O'Connell DL, Gibberd RW, et al. Trends in survival and excess risk of death after diagnosis of cancer in 1980-1996 in New South Wales, Australia. Int J Cancer, 2006; 119, 894−900. doi:  10.1002/ijc.21909
[87] Inoue S, Hosono S, Ito H, et al. Improvement in 5-year relative survival in cancer of the corpus uteri from 1993-2000 to 2001-2006 in Japan. J Epidemiol, 2018; 28, 75−80. doi:  10.2188/jea.JE20170008
[88] Ioka A, Tsukuma H, Ajiki W, et al. Influence of hospital procedure volume on uterine cancer survival in Osaka, Japan. Cancer Sci, 2005; 96, 689−94. doi:  10.1111/j.1349-7006.2005.00094.x
[89] Yagi A, Ueda Y, Ikeda S, et al. Improved long-term survival of corpus cancer in Japan: a 40-year population-based analysis. Int J Cancer, 2022; 150, 232−42. doi:  10.1002/ijc.33799
[90] Ha HI, Chang HK, Park SJ, et al. The incidence and survival of cervical, ovarian, and endometrial cancer in Korea, 1999-2017: Korea Central Cancer Registry. Obstet Gynecol Sci, 2021; 64, 444−53. doi:  10.5468/ogs.21116
[91] Dalton SO, Olsen MH, Johansen C, et al. Socioeconomic inequality in cancer survival - changes over time. A population-based study, Denmark, 1987-2013. Acta Oncol, 2019; 58, 737−44. doi:  10.1080/0284186X.2019.1566772
[92] Ojamaa K, Veerus P, Baburin A, et al. Increasing incidence and survival of corpus uteri cancer in Estonia over the past two decades. Cancer Epidemiol, 2019; 62, 101566. doi:  10.1016/j.canep.2019.101566
[93] Dickman PW, Hakulinen T, Luostarinen T, et al. Survival of cancer patients in Finland 1955-1994. Acta Oncol, 1999; 38 Suppl 12, 1-103.
[94] Boll D, Verhoeven RHA, van der Aa MA, et al. Incidence and survival trends of uncommon corpus uteri malignancies in the Netherlands, 1989-2008. Int J Gynecol Cancer, 2012; 22, 599−606. doi:  10.1097/IGC.0b013e318244cedc
[95] Zhu J, Xu YY, Zhang YH, et al. Analysis of the survival trend of ovary cancer in Qidong City, Jiangsu Province from 1977 to 2016. Journal of Modern Oncology,2023; 31:1731-5. (In Chinese)
[96] Loka A, Tsukuma H, Ajiki W, et al. Ovarian cancer incidence and survival by histologic type in Osaka, Japan. Cancer Sci, 2003; 94, 292−6. doi:  10.1111/j.1349-7006.2003.tb01435.x
[97] Ries LAG. Ovarian cancer: Survival and treatment differences by age. Cancer, 1993; 71, 524−9.
[98] Cabasag CJ, Butler J, Arnold M, et al. Exploring variations in ovarian cancer survival by age and stage (ICBP SurvMark-2): a population-based study. Gynecol Oncol, 2020; 157, 234−44. doi:  10.1016/j.ygyno.2019.12.047
[99] Lambert P, Galloway K, Altman A, et al. Ovarian cancer in Manitoba: trends in incidence and survival, 1992-2011. Curr Oncol, 2017; 24, 78−84. doi:  10.3747/co.24.3312
[100] Karim-Kos HE, de Vries E, Soerjomataram I, et al. Recent trends of cancer in Europe: a combined approach of incidence, survival and mortality for 17 cancer sites since the 1990s. Eur J Cancer, 2008; 44, 1345−89. doi:  10.1016/j.ejca.2007.12.015
[101] Hamidou Z, Causeret S, Dabakuyo TS, et al. Population-based study of ovarian cancer in Côte d'Or: prognostic factors and trends in relative survival rates over the last 20 years. BMC Cancer, 2010; 10, 622. doi:  10.1186/1471-2407-10-622
[102] Gondos A, Holleczek B, Arndt V, et al. Trends in population-based cancer survival in Germany: to what extent does progress reach older patients? Ann Oncol. 2007; 18:1253-9. )
[103] Karim-Kos HE, Kiemeney LALM, Louwman MWJ, et al. Progress against cancer in the Netherlands since the late 1980s: An epidemiological evaluation. Int J Cancer, 2012; 130, 2981−9. doi:  10.1002/ijc.26315
[104] Balvert-Locht HR, Coebergh JWW, Hop WCJ, et al. Improved prognosis of ovarian cancer in The Netherlands during the period 1975-1985: a registry-based study. Gynecol Oncol, 1991; 42, 3−8. doi:  10.1016/0090-8258(91)90222-Q
[105] Akbari A, Azizmohammad Looha M, Moradi A, Akbari ME. Ovarian Cancer in Iran: National Based Study. Iran J Public Health. 2023; 52:797-808.
[106] Wei KR, Liang ZH, Cen HS. Net survival of cancers in Zhongshan city, Guangdong province, 1995-2009. China Cancer, 2016; 25, 747−51. (In Chinese
[107] Wei KR, Liang ZH, Li ZM. Net survival of major cancers in Zhongshan city of Guangdong province from 2003 to 2013. China Cancer, 2020; 29, 103−7. (In Chinese
[108] Allemani C, Matsuda T, Di Carlo V, et al. Global surveillance of trends in cancer survival 2000–14 (CONCORD-3): analysis of individual records for 37 513 025 patients diagnosed with one of 18 cancers from 322 population-based registries in 71 countries. Lancet, 2018; 391, 1023−75. doi:  10.1016/S0140-6736(17)33326-3
[109] Allemani C, Weir HK, Carreira H, et al. Global surveillance of cancer survival 1995-2009: analysis of individual data for 25 676 887 patients from 279 population-based registries in 67 countries (CONCORD-2). Lancet, 2015; 385, 977−1010. doi:  10.1016/S0140-6736(14)62038-9
[110] Lim GH, Wong CS, Chow KY, et al. Trends in long-term cancer survival in Singapore: 1968-2002. Ann Acad Med Singap, 2009; 38, 99−105. doi:  10.47102/annals-acadmedsg.V38N2p99
[111] Zeng HM, Chen WQ, Zheng RS, et al. Changing cancer survival in China during 2003–15: a pooled analysis of 17 population-based cancer registries. Lancet Glob Health, 2018; 6, e555−67. doi:  10.1016/S2214-109X(18)30127-X
[112] Quaresma M, Coleman MP, Rachet B. 40-year trends in an index of survival for all cancers combined and survival adjusted for age and sex for each cancer in England and Wales, 1971-2011: A population-based study. Lancet, 2015; 385, 1206−18. doi:  10.1016/S0140-6736(14)61396-9
[113] Sant M, Lopez MDC, Agresti R, et al. Survival of women with cancers of breast and genital organs in Europe 1999-2007: Results of the EUROCARE-5 study. Eur J Cancer, 2015; 51, 2191−205. doi:  10.1016/j.ejca.2015.07.022
[114] Antunes L, Roche L, José BM. Trends in net survival from corpus uteri cancer in six European Latin countries: results from the SUDCAN population-based study. Eur J Cancer Prev, 2017; 26, S100−6. doi:  10.1097/CEJ.0000000000000294
[115] Antunes L, Santos LL, Bento MJ. Survival from cancer in the north region of Portugal: results from the first decade of the millennium. Eur J Cancer Prev, 2017; 26, S170−5. doi:  10.1097/CEJ.0000000000000378
[116] Chen TH, Jansen L, Gondos A, et al. Survival of endometrial cancer patients in Germany in the early 21st century: a period analysis by age, histology, and stage. BMC Cancer, 2012; 12, 128. doi:  10.1186/1471-2407-12-128
[117] Jansen L, Castro FA, Gondos A, et al. Recent cancer survival in Germany: an analysis of common and less common cancers. Int J Cancer, 2015; 136, 2649−58. doi:  10.1002/ijc.29316
[118] Cowppli-Bony A, Uhry Z, Remontet L, et al. Survival of solid cancer patients in France, 1989-2013: a population-based study. Eur J Cancer Prev, 2017; 26, 461−8. doi:  10.1097/CEJ.0000000000000372
[119] Innos K, Baburin A, Aareleid T. Cancer patient survival in Estonia 1995-2009: Time trends and data quality. Cancer Epidemiol, 2014; 38, 253−8. doi:  10.1016/j.canep.2014.03.008
[120] Arnold M, Rutherford MJ, Bardot A, et al. Progress in cancer survival, mortality, and incidence in seven high-income countries 1995-2014 (ICBP SURVMARK-2): a population-based study. Lancet Oncol, 2019; 20, 1493−505. doi:  10.1016/S1470-2045(19)30456-5
[121] dos Santos FLC, Wojciechowska U, Michalek IM, et al. Progress in cancer survival across last two decades: a nationwide study of over 1.2 million Polish patients diagnosed with the most common cancers. Cancer Epidemiol, 2022; 78, 102147. doi:  10.1016/j.canep.2022.102147
[122] Myklebust TÅ, Andersson T, Bardot A, et al. Can different definitions of date of cancer incidence explain observed international variation in cancer survival? An ICBP SURVMARK-2 study. Cancer Epidemiol, 2020; 67, 101759. doi:  10.1016/j.canep.2020.101759
[123] Ojamaa K, Veerus P, Baburin A, et al. Time trends in ovarian cancer survival in Estonia by age and stage. Int J Gynecol Cancer, 2017; 27, 44−9. doi:  10.1097/IGC.0000000000000858
[124] Walters S, Benitez-Majano S, Muller P, et al. Is England closing the international gap in cancer survival?. Br J Cancer, 2015; 113, 848−60. doi:  10.1038/bjc.2015.265
[125] Levi F, Randimbison L, Te VC, et al. Trends in cancer survival in Vaud, Switzerland. Eur J Cancer, 1992; 28, 1490−5. doi:  10.1016/0959-8049(92)90551-C
[126] Ha HI, Chang HK, Park SJ, et al. Correction of Funding information: The incidence and survival of cervical, ovarian, and endometrial cancer in Korea, 1999-2017: Korea Central Cancer Registry. Obstet Gynecol Sci, 2022; 65, 384. doi:  10.5468/ogs.21116.e1
[127] Jun J, Zhang YH, Chen YS, et al. Analysis of survival rate of cervical cancer patients during 2001-2007 in Qidong City. Chin J Clin Oncol Rehab, 2011; 18, 193−6. (In Chinese
[128] Lu HS, Li L, Cheng YR, et al. Timely estimates of 5-year relative survival for patients with cervical cancer: a period analysis using cancer registry data from Taizhou, Eastern China. Front Public Health, 2022; 10, 926058. doi:  10.3389/fpubh.2022.926058
[129] Choi HCW, Lam KO, Pang HHM, et al. Global comparison of cancer outcomes: standardization and correlation with healthcare expenditures. BMC Public Health, 2019; 19, 1065. doi:  10.1186/s12889-019-7384-y
[130] GBD 2019 Human Resources for Health Collaborators. Measuring the availability of human resources for health and its relationship to universal health coverage for 204 countries and territories from 1990 to 2019: a systematic analysis for the Global Burden of Disease Study 2019. Lancet, 2022; 399, 2129−54. doi:  10.1016/S0140-6736(22)00532-3
[131] Riano I, Contreras-Chavez P, Pabon CM, et al. An overview of cervical cancer prevention and control in Latin America and the Caribbean countries. Hematol Oncol Clin North Am, 2024; 38, 13−33. doi:  10.1016/j.hoc.2023.05.012
[132] Goss PE, Lee BL, Badovinac-Crnjevic T, et al. Planning cancer control in Latin America and the Caribbean. Lancet Oncol, 2013; 14, 391−436. doi:  10.1016/S1470-2045(13)70048-2
[133] Denny L. Control of cancer of the cervix in low- and middle-income countries. Ann Surg Oncol, 2015; 22, 728−33.
[134] Bouvard V, Wentzensen N, Mackie A, et al. The IARC perspective on cervical cancer screening. N Engl J Med, 2021; 385, 1908−18. doi:  10.1056/NEJMsr2030640
[135] Arbyn M, Ronco G, Anttila A, et al. Evidence regarding human papillomavirus testing in secondary prevention of cervical cancer. Vaccine, 2012; 30 Suppl 5, F88-99.
[136] Lee SY. Tailored therapy based on molecular characteristics in endometrial cancer. BioMed Res Int, 2021; 2021, 2068023.
[137] van Weelden WJ, Massuger LFAG, ENITEC, et al. Anti-estrogen treatment in endometrial cancer: a systematic review. Front Oncol, 2019; 9, 359. doi:  10.3389/fonc.2019.00359
[138] Urick ME, Bell DW. Clinical actionability of molecular targets in endometrial cancer. Nat Rev Cancer, 2019; 19, 510−21. doi:  10.1038/s41568-019-0177-x
[139] Fader AN, Roque DM, Siegel E, et al. Randomized phase II trial of carboplatin-paclitaxel versus carboplatin-paclitaxel-trastuzumab in uterine serous carcinomas that overexpress human epidermal growth factor receptor 2/neu. J Clin Oncol, 2018; 36, 2044−51. doi:  10.1200/JCO.2017.76.5966
[140] Levine DA, The Cancer Genome Atlas Research Network. Integrated genomic characterization of endometrial carcinoma. Nature, 2013; 497, 67−73. doi:  10.1038/nature12113
[141] Aghajanian C, Filiaci V, Dizon DS, et al. A phase II study of frontline paclitaxel/carboplatin/bevacizumab, paclitaxel/carboplatin/temsirolimus, or ixabepilone/carboplatin/bevacizumab in advanced/recurrent endometrial cancer. Gynecol Oncol, 2018; 150, 274−81. doi:  10.1016/j.ygyno.2018.05.018
[142] Lorusso D, Ferrandina G, Colombo N, et al. Carboplatin-paclitaxel compared to carboplatin-paclitaxel-bevacizumab in advanced or recurrent endometrial cancer: MITO END-2 - a randomized phase II trial. Gynecol Oncol, 2019; 155, 406−12. doi:  10.1016/j.ygyno.2019.10.013
[143] Latha TS, Panati K, Gowd DSK, et al. Ovarian cancer biology and immunotherapy. Int Rev Immunol, 2014; 33, 428−40. doi:  10.3109/08830185.2014.921161
[144] Torre LA, Trabert B, DeSantis CE, et al. Ovarian cancer statistics, 2018. CA Cancer J Clin, 2018; 68, 284−96. doi:  10.3322/caac.21456
[145] Yang C, Xia BR, Zhang ZC, et al. Immunotherapy for ovarian cancer: adjuvant, combination, and neoadjuvant. Front Immunol, 2020; 11, 577869. doi:  10.3389/fimmu.2020.577869
[146] Zhang H, Liu XY, Penn-Kekana L, et al. A systematic review of the profile and density of the maternal and child health workforce in China. Hum Resour Health, 2021; 19, 125. doi:  10.1186/s12960-021-00662-4
[147] Song YF, Liu XX, Yin ZD, et al. Human papillomavirus vaccine coverage among the 9-45-year-old female population of China in 2018-2020. Chin J Vaccines Immunization, 2021; 27, 570−5. (In Chinese
[148] Tabatabaei FS, Saeedian A, Azimi A, et al. Evaluation of survival rate and associated factors in patients with cervical cancer: a retrospective cohort study. J Res Health Sci, 2022; 22, e00552. doi:  10.34172/jrhs.2022.87
[149] Moore DH. Cervical cancer. Obstet Gynecol, 2006; 107, 1152−61. doi:  10.1097/01.AOG.0000215986.48590.79
[150] Solmaz U, Mat E, Dereli ML, et al. Stage-III and -IV endometrial cancer: A single oncology centre review of 104 cases. J Obstet Gynaecol, 2016; 36, 81−6. doi:  10.3109/01443615.2015.1041890
[151] Guarneri V, Barbieri E, Dieci MV, et al. Timing for starting second-line therapy in recurrent ovarian cancer. Expert Rev Anticancer Ther, 2011; 11, 49−55. doi:  10.1586/era.10.204
[152] Schorge JO, Garrett LA, Goodman A. Cytoreductive surgery for advanced ovarian cancer: quo vadis?. Oncology (Williston Park), 2011; 25, 928−34.
[153] Lea JS, Lin KY. Cervical cancer. Obstet Gynecol Clin North Am, 2012; 39, 233−53. doi:  10.1016/j.ogc.2012.02.008
[154] Meng YF, Chu T, Lin ST, et al. Clinicopathological characteristics and prognosis of cervical cancer with different histological types: A population-based cohort study. Gynecol Oncol, 2021; 163, 545−51. doi:  10.1016/j.ygyno.2021.10.007
[155] Amant F, Moerman P, Neven P, et al. Endometrial cancer. Lancet, 2005; 366, 491−505. doi:  10.1016/S0140-6736(05)67063-8
[156] Tai YJ, Chiang CJ, Chiang YC, et al. Age-specific trend and birth cohort effect on different histologic types of uterine corpus cancers. Sci Rep, 2023; 13, 1019. doi:  10.1038/s41598-022-21669-4
[157] Mori S, Gotoh O, Kiyotani K, et al. Genomic alterations in gynecological malignancies: histotype-associated driver mutations, molecular subtyping schemes, and tumorigenic mechanisms. J Hum Genet, 2021; 66, 853−68. doi:  10.1038/s10038-021-00940-y
[158] Granier C, Gey A, Roncelin S, et al. Immunotherapy in older patients with cancer. Biomed J, 2021; 44, 260−271. doi:  10.1016/j.bj.2020.07.009
[159] Vitale SG, Capriglione S, Zito G, et al. Management of endometrial, ovarian and cervical cancer in the elderly: current approach to a challenging condition. Arch Gynecol Obstet, 2019; 299, 299−315. doi:  10.1007/s00404-018-5006-z
[160] Fentiman IS. Are the elderly receiving appropriate treatment for cancer?. Ann Oncol, 1996; 7, 657−8. doi:  10.1093/oxfordjournals.annonc.a010712
[161] Yamamoto M, Yoshida Y, Itani Y, et al. How do doctors choose treatment for older gynecological cancer patients? A Japanese Gynecologic Oncology Group survey of gynecologic oncologists. Int J Clin Oncol, 2020; 25, 741−5. doi:  10.1007/s10147-019-01574-z
[162] Goodwin JS, Hunt WC, Samet JM. Determinants of cancer therapy in elderly patients. Cancer, 1993; 72, 594−601. doi:  10.1002/1097-0142(19930715)72:2<594::AID-CNCR2820720243>3.0.CO;2-#
[163] Carney ME, Lancaster JM, Ford C, et al. A population-based study of patterns of care for ovarian cancer: who is seen by a gynecologic oncologist and who is not?. Gynecol Oncol, 2002; 84, 36−42. doi:  10.1006/gyno.2001.6460
[164] Liu Z, Zhao LY, Man QQ, et al. Dietary micronutrients intake status among Chinese elderly people living at home: data from CNNHS 2010-2012. Nutrients, 2019; 11, 1787. doi:  10.3390/nu11081787
[165] Ongan D, Rakıcıoğlu N. Nutritional status and dietary intake of institutionalized elderly in Turkey: a cross-sectional, multi-center, country representative study. Arch Gerontol Geriatr, 2015; 61, 271−6. doi:  10.1016/j.archger.2015.05.004